RxDoctor Payments Data

Emily Tommolino, MD

Gastroenterology · Ypsilanti, MINPI 1578908000

Payments from drug & device makers

$4,273in general payments, 2019–2025

Across 183 payments — averaging $23.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$896
  • AbbVie$688
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$639
  • Bristol Myers Squibb$496
  • Takeda Pharmaceuticals U.S.A., Inc.$335
  • Gilead$312
  • plus $906 from 15 others

What the payments were for

  • Food & beverage$4,17498%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,273 in reported general payments places this provider in the 60th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$89,535
Medicare patients
309
Services billed
1,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab14$90,789
CreonLipase/Protease/Amylase13$33,137
LinzessLinaclotide34$22,813
IbsrelaTenapanor Hcl11$17,469
Mesalamine12$9,128
TrulancePlecanatide13$7,004
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl83$1,579
CholestyramineCholestyramine (With Sugar)11$1,060
Pantoprazole Sodium23$523
Famotidine35$445
Omeprazole30$428
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg15$413
Dicyclomine Hcl11$390
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl16$344
Metronidazole11$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$688$55,95047 claims
Ardelyx, Inc.Ibsrela$99$17,46911 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$639$7,00413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Ypsilanti

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →